
Please try another search
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Vidadi M. Yusibov | 64 | 2004 | Member of Scientific Advisory Board |
Robert L. Erwin | 72 | 2008 | Member of Scientific Advisory Board |
Timothy Blackwell | - | 2014 | Member of Clinical Advisory Board |
Thomas A. Medsger | - | 2014 | Member of Clinical Advisory Board |
Alexandra Kropotova | 53 | 2020 | Independent Director |
Richard M. Silver | - | 2014 | Member of Clinical Advisory Board |
Martin B. Brenner | 55 | 2021 | CEO, Chief Scientific Officer & Director |
J. Terrill Huggins | - | 2014 | Member of Clinical Advisory Board |
Evert B. Schimmelpennink | 53 | 2019 | Independent Director |
William D. Clark | 56 | 2021 | Independent Chairman |
Antonio Parada | 57 | 2024 | Independent Director |
David A. Arkowitz | 64 | 2024 | Independent Director |
Gary L. Sender | 63 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review